Cargando…

Development of a Plasmodium vivax biobank for functional ex vivo assays

BACKGROUND: Plasmodium vivax is the second most prevalent cause of malaria yet remains challenging to study due to the lack of a continuous in vitro culture system, highlighting the need to establish a biobank of clinical isolates with multiple freezes per sample for use in functional assays. Differ...

Descripción completa

Detalles Bibliográficos
Autores principales: Dash, Rashmi, Skillman, Kristen M., Pereira, Ligia, Mascarenhas, Anjali, Dass, Sheena, Walke, Jayashri, Almeida, Anvily, Fernandes, Mezia, Gomes, Edwin, White, John, Chery-Karschney, Laura, Khandeparkar, Anar, Rathod, Pradipsinh K., Duraisingh, Manoj T., Kanjee, Usheer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470152/
https://www.ncbi.nlm.nih.gov/pubmed/37653486
http://dx.doi.org/10.1186/s12936-023-04668-2
_version_ 1785099623852933120
author Dash, Rashmi
Skillman, Kristen M.
Pereira, Ligia
Mascarenhas, Anjali
Dass, Sheena
Walke, Jayashri
Almeida, Anvily
Fernandes, Mezia
Gomes, Edwin
White, John
Chery-Karschney, Laura
Khandeparkar, Anar
Rathod, Pradipsinh K.
Duraisingh, Manoj T.
Kanjee, Usheer
author_facet Dash, Rashmi
Skillman, Kristen M.
Pereira, Ligia
Mascarenhas, Anjali
Dass, Sheena
Walke, Jayashri
Almeida, Anvily
Fernandes, Mezia
Gomes, Edwin
White, John
Chery-Karschney, Laura
Khandeparkar, Anar
Rathod, Pradipsinh K.
Duraisingh, Manoj T.
Kanjee, Usheer
author_sort Dash, Rashmi
collection PubMed
description BACKGROUND: Plasmodium vivax is the second most prevalent cause of malaria yet remains challenging to study due to the lack of a continuous in vitro culture system, highlighting the need to establish a biobank of clinical isolates with multiple freezes per sample for use in functional assays. Different methods for cryopreserving parasite isolates were compared and subsequently the most promising one was validated. Enrichment of early- and late-stage parasites and parasite maturation were quantified to facilitate assay planning. METHODS: In order to compare cryopreservation protocols, nine clinical P. vivax isolates were frozen with four glycerolyte-based mixtures. Parasite recovery post thaw, post KCl-Percoll enrichment and in short-term in vitro culture was measured via slide microscopy. Enrichment of late-stage parasites by magnetic activated cell sorting (MACS) was measured. Short and long-term storage of parasites at either − 80 °C or liquid nitrogen were also compared. RESULTS: Of the four cryopreservation mixtures, one mixture (glycerolyte:serum:RBC at a 2.5:1.5:1 ratio) resulted in improved parasite recovery and statistically significant (P < 0.05) enhancement in parasite survival in short-term in vitro culture. A parasite biobank was subsequently generated using this protocol resulting in a collection of 106 clinical isolates, each with 8 vials. The quality of the biobank was validated by measuring several factors from 47 thaws: the average reduction in parasitaemia post-thaw (25.3%); the average fold enrichment post KCl-Percoll (6.65-fold); and the average percent recovery of parasites (22.0%, measured from 30 isolates). During short-term in vitro culture, robust maturation of ring stage parasites to later stages (> 20% trophozoites, schizonts and gametocytes) was observed in 60.0% of isolates by 48 h. Enrichment of mature parasite stages via MACS showed good reproducibility, with an average of 30.0% post-MACS parasitaemia and an average of 5.30 × 10(5) parasites/vial. Finally, the effect of storage temperature was tested, and no large impacts from short-term (7 days) or long-term (7–10 years) storage at − 80 °C on parasite recovery, enrichment or viability was observed. CONCLUSIONS: Here, an optimized freezing method for P. vivax clinical isolates is demonstrated as a template for the generation and validation of a parasite biobank for use in functional assays. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12936-023-04668-2.
format Online
Article
Text
id pubmed-10470152
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104701522023-09-01 Development of a Plasmodium vivax biobank for functional ex vivo assays Dash, Rashmi Skillman, Kristen M. Pereira, Ligia Mascarenhas, Anjali Dass, Sheena Walke, Jayashri Almeida, Anvily Fernandes, Mezia Gomes, Edwin White, John Chery-Karschney, Laura Khandeparkar, Anar Rathod, Pradipsinh K. Duraisingh, Manoj T. Kanjee, Usheer Malar J Research BACKGROUND: Plasmodium vivax is the second most prevalent cause of malaria yet remains challenging to study due to the lack of a continuous in vitro culture system, highlighting the need to establish a biobank of clinical isolates with multiple freezes per sample for use in functional assays. Different methods for cryopreserving parasite isolates were compared and subsequently the most promising one was validated. Enrichment of early- and late-stage parasites and parasite maturation were quantified to facilitate assay planning. METHODS: In order to compare cryopreservation protocols, nine clinical P. vivax isolates were frozen with four glycerolyte-based mixtures. Parasite recovery post thaw, post KCl-Percoll enrichment and in short-term in vitro culture was measured via slide microscopy. Enrichment of late-stage parasites by magnetic activated cell sorting (MACS) was measured. Short and long-term storage of parasites at either − 80 °C or liquid nitrogen were also compared. RESULTS: Of the four cryopreservation mixtures, one mixture (glycerolyte:serum:RBC at a 2.5:1.5:1 ratio) resulted in improved parasite recovery and statistically significant (P < 0.05) enhancement in parasite survival in short-term in vitro culture. A parasite biobank was subsequently generated using this protocol resulting in a collection of 106 clinical isolates, each with 8 vials. The quality of the biobank was validated by measuring several factors from 47 thaws: the average reduction in parasitaemia post-thaw (25.3%); the average fold enrichment post KCl-Percoll (6.65-fold); and the average percent recovery of parasites (22.0%, measured from 30 isolates). During short-term in vitro culture, robust maturation of ring stage parasites to later stages (> 20% trophozoites, schizonts and gametocytes) was observed in 60.0% of isolates by 48 h. Enrichment of mature parasite stages via MACS showed good reproducibility, with an average of 30.0% post-MACS parasitaemia and an average of 5.30 × 10(5) parasites/vial. Finally, the effect of storage temperature was tested, and no large impacts from short-term (7 days) or long-term (7–10 years) storage at − 80 °C on parasite recovery, enrichment or viability was observed. CONCLUSIONS: Here, an optimized freezing method for P. vivax clinical isolates is demonstrated as a template for the generation and validation of a parasite biobank for use in functional assays. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12936-023-04668-2. BioMed Central 2023-08-31 /pmc/articles/PMC10470152/ /pubmed/37653486 http://dx.doi.org/10.1186/s12936-023-04668-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Dash, Rashmi
Skillman, Kristen M.
Pereira, Ligia
Mascarenhas, Anjali
Dass, Sheena
Walke, Jayashri
Almeida, Anvily
Fernandes, Mezia
Gomes, Edwin
White, John
Chery-Karschney, Laura
Khandeparkar, Anar
Rathod, Pradipsinh K.
Duraisingh, Manoj T.
Kanjee, Usheer
Development of a Plasmodium vivax biobank for functional ex vivo assays
title Development of a Plasmodium vivax biobank for functional ex vivo assays
title_full Development of a Plasmodium vivax biobank for functional ex vivo assays
title_fullStr Development of a Plasmodium vivax biobank for functional ex vivo assays
title_full_unstemmed Development of a Plasmodium vivax biobank for functional ex vivo assays
title_short Development of a Plasmodium vivax biobank for functional ex vivo assays
title_sort development of a plasmodium vivax biobank for functional ex vivo assays
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470152/
https://www.ncbi.nlm.nih.gov/pubmed/37653486
http://dx.doi.org/10.1186/s12936-023-04668-2
work_keys_str_mv AT dashrashmi developmentofaplasmodiumvivaxbiobankforfunctionalexvivoassays
AT skillmankristenm developmentofaplasmodiumvivaxbiobankforfunctionalexvivoassays
AT pereiraligia developmentofaplasmodiumvivaxbiobankforfunctionalexvivoassays
AT mascarenhasanjali developmentofaplasmodiumvivaxbiobankforfunctionalexvivoassays
AT dasssheena developmentofaplasmodiumvivaxbiobankforfunctionalexvivoassays
AT walkejayashri developmentofaplasmodiumvivaxbiobankforfunctionalexvivoassays
AT almeidaanvily developmentofaplasmodiumvivaxbiobankforfunctionalexvivoassays
AT fernandesmezia developmentofaplasmodiumvivaxbiobankforfunctionalexvivoassays
AT gomesedwin developmentofaplasmodiumvivaxbiobankforfunctionalexvivoassays
AT whitejohn developmentofaplasmodiumvivaxbiobankforfunctionalexvivoassays
AT cherykarschneylaura developmentofaplasmodiumvivaxbiobankforfunctionalexvivoassays
AT khandeparkaranar developmentofaplasmodiumvivaxbiobankforfunctionalexvivoassays
AT rathodpradipsinhk developmentofaplasmodiumvivaxbiobankforfunctionalexvivoassays
AT duraisinghmanojt developmentofaplasmodiumvivaxbiobankforfunctionalexvivoassays
AT kanjeeusheer developmentofaplasmodiumvivaxbiobankforfunctionalexvivoassays